Nathan G. Brower
Known title: EVP, General CounselCIK: 0001723752
Associated companies
Transaction History
| NATR | ▼ Sell | Open Market | 12,015 | $262K | 5/21/2026 | View on chart |
| NATR | ▲ Buy | Grant | 9,001 | $0 | 5/15/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 2,235 | $0 | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 645 | $17K | 5/5/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 1,526 | $0 | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 441 | $11K | 5/5/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 2,014 | $0 | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 582 | $15K | 5/5/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,289 | $35K | 4/20/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 953 | $24K | 3/11/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,363 | $34K | 3/10/2026 | View on chart |
| NATR | ▲ Buy | Option Exercise | 1,086 | $0 | 3/6/2026 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 371 | $9K | 3/6/2026 | View on chart |
| NATR | ▲ Buy | Grant | 7,250 | $182K | 3/6/2026 | View on chart |
| NATR | ▼ Sell | Other | 7,250 | — | 3/6/2026 | View on chart |
| NATR | ▼ Sell | Gift | 1,500 | $31K | 11/24/2025 | View on chart |
| NATR | ▼ Sell | Open Market | 3,800 | $79K | 11/14/2025 | View on chart |
| NATR | ▲ Buy | Option Exercise | 1,008 | $0 | 11/4/2025 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 285 | $4K | 11/4/2025 | View on chart |
| NATR | ▲ Buy | Option Exercise | 2,235 | $0 | 11/4/2025 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 700 | $10K | 11/4/2025 | View on chart |
| NATR | ▼ Sell | Open Market | 9,996 | $165K | 8/13/2025 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,491 | $22K | 7/21/2025 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 991 | $14K | 3/11/2025 | View on chart |
| NATR | ▲ Buy | Grant | 11,966 | $176K | 3/10/2025 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,376 | $21K | 7/21/2024 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,534 | $30K | 4/20/2024 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 748 | $15K | 3/26/2024 | View on chart |
| NATR | ▲ Buy | Grant | 8,687 | $0 | 3/11/2024 | View on chart |
| NATR | ▼ Sell | Open Market | 3,999 | $69K | 11/21/2023 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,294 | $18K | 7/21/2023 | View on chart |
| NATR | ▼ Sell | Open Market | 3,128 | $34K | 5/19/2023 | View on chart |
| NATR | ▼ Sell | Open Market | 8,268 | $91K | 5/18/2023 | View on chart |
| NATR | ▲ Buy | Grant | 13,408 | $0 | 4/20/2023 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 1,302 | $13K | 3/30/2023 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 646 | $7K | 3/26/2023 | View on chart |
| NATR | ▼ Sell | Open Market | 4,972 | $41K | 12/9/2022 | View on chart |
| NATR | ▲ Buy | Grant | 13,091 | $0 | 7/21/2022 | View on chart |
| NATR | ▲ Buy | Option Exercise | 1,913 | — | 4/6/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 462 | $8K | 4/6/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 573 | $10K | 3/30/2022 | View on chart |
| NATR | ▼ Sell | Tax Withholding | 637 | $11K | 3/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nature's Sunshine Q2 Earnings Reviewed Against Peers
A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.
Nature's Sunshine Q2 Earnings Reviewed Against Peers. A recent analysis compared Nature's Sunshine's second-quarter results with other personal care companies. This review helps investors understand how the stock performed relative to its sector during that period. The company currently trades with a trailing P/E ratio of 13.3, while analysts maintain an average price target of $30.50.